Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy and bone marrow transplantation.

E D Thomas

    Seminars in Oncology
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Cyclophosphamide (CY) toxicity varies by organ and species, with cardiac issues limiting doses in monkeys. CY is crucial for conditioning patients for bone marrow transplantation, enabling engraftment in aplastic anemia and thalassemia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.

    Transplantation·1992
    Same author

    Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status.

    Genomics·1992
    Same author

    Bone marrow transplantation: past experiences and future prospects.

    Seminars in oncology·1992
    Same author

    Donor alloreactivity may predict acute graft-versus-host disease in HLA-matched bone marrow transplantation for leukemia in early remission.

    European journal of haematology·1992
    Same author

    Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.

    Bone marrow transplantation·1992
    Same author

    Acceptance of the George M. Kober Medal.

    Transactions of the Association of American Physicians·1992

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Background:

    • Bone marrow toxicity is a major limitation for high-dose chemotherapy.
    • Bone marrow transplantation (BMT) mitigates marrow toxicity but not other organ toxicities.
    • Cyclophosphamide (CY) is a chemotherapeutic agent used in BMT conditioning regimens.

    Purpose of the Study:

    • To delineate the dose-limiting toxicities of cyclophosphamide (CY) therapy in animal models.
    • To evaluate the efficacy of CY in conditioning patients for bone marrow transplantation (BMT).
    • To review current BMT regimens, complications, and future directions.

    Main Methods:

    • Animal studies in mice, rats, rhesus monkeys, and dogs to determine CY toxicity.
    • Clinical application of CY in conditioning patients with aplastic anemia, thalassemia, and leukemia for BMT.

    Related Experiment Videos

  • Review of historical and current BMT protocols, including radiotherapy and immunosuppressive strategies.

    • Main Results:

    • In dogs, 100 mg/kg CY was lethal without marrow support but allowed engraftment with autologous marrow.
    • In monkeys, cardiac toxicity limited CY dose to 180 mg/kg for successful allogeneic engraftment.
    • CY conditioning (50 mg/kg x 4 days) yields ~80% survival for aplastic anemia and ~75% for thalassemia patients.

    Conclusions:

    • CY dose-limiting toxicities are organ- and species-specific, necessitating careful regimen design.
    • CY is a vital component of conditioning regimens for various hematologic disorders requiring BMT.
    • Ongoing research focuses on optimizing BMT protocols to improve survival and reduce complications.